Active, Not Recruiting
An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer - CA018-001
Updated: 15 November, 2019 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Active, Not Recruiting
Treatment Options
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Advanced Non Small Cell Lung Cancer (NSCLC) - Eastern Cooperative Oncology Group (ECOG) Performance status of ≤ 1 - Life expectancy of at least 3 months from most recent chemotherapy or immunotherapy treatment - Must have at least 1 lesion with measurable disease Exclusion Criteria: - Subjects with certain mutations that have not been treated with a targeted therapy prior to enrollment - Subjects who need daily oxygen therapy - People with autoimmune disease Other protocol defined inclusion/exclusion criteria could apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
